These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19149572)

  • 1. The effects of medications used for the management of dyslipidemia on postprandial lipemia.
    Tentolouris N; Eleftheriadou I; Katsilambros N
    Curr Med Chem; 2009; 16(2):203-17. PubMed ID: 19149572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of fibrates in postprandial lipemia.
    Kolovou GD; Kostakou PM; Anagnostopoulou KK; Cokkinos DV
    Am J Cardiovasc Drugs; 2008; 8(4):243-55. PubMed ID: 18690758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism.
    Eleftheriadou I; Grigoropoulou P; Katsilambros N; Tentolouris N
    Curr Diabetes Rev; 2008 Nov; 4(4):340-56. PubMed ID: 18991602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of dyslipoproteinemia in the metabolic syndrome.
    Steinmetz A; Fenselau S; Schrezenmeir J
    Exp Clin Endocrinol Diabetes; 2001; 109(4):S548-59. PubMed ID: 11453042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrates in combination with statins in the management of dyslipidemia.
    Jacobson TA; Zimmerman FH
    J Clin Hypertens (Greenwich); 2006 Jan; 8(1):35-41; quiz 42-3. PubMed ID: 16407687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease.
    Mero N; Malmström R; Steiner G; Taskinen MR; Syvänne M
    Atherosclerosis; 2000 May; 150(1):167-77. PubMed ID: 10781648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
    Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
    Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of dyslipidemia--what's left in the pipeline?
    Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M
    ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of statins on postprandial lipemia.
    Kolovou GD; Anagnostopoulou KK; Salpea KD; Daskalopoulou SS; Mikhailidis DP
    Curr Drug Targets; 2007 Apr; 8(4):551-60. PubMed ID: 17430126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of increasing doses of simvastatin on fasting lipoprotein subfractions, and the effect of high-dose simvastatin on postprandial chylomicron remnant clearance in normotriglyceridemic patients with premature coronary sclerosis.
    van Wijk JP; Buirma R; van Tol A; Halkes CJ; De Jaegere PP; Plokker HW; van der Helm YJ; Castro Cabezas M
    Atherosclerosis; 2005 Jan; 178(1):147-55. PubMed ID: 15585212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients.
    Cassader M; Gambino R; Musso G; Depetris N; Mecca F; Cavallo-Perin P; Pacini G; Rizzetto M; Pagano G
    Lipids; 2001 Oct; 36(10):1117-24. PubMed ID: 11768156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel strategies for managing dyslipidemia: treatment beyond statins.
    Ling H; Burns TL; Hilleman DE
    Postgrad Med; 2012 Nov; 124(6):43-54. PubMed ID: 23322138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism?
    Battula SB; Fitzsimons O; Moreno S; Owens D; Collins P; Johnson A; Tomkin GH
    Metabolism; 2000 Aug; 49(8):1049-54. PubMed ID: 10954025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Cardiovasc Diabetol; 2006 Sep; 5():20. PubMed ID: 17002798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postprandial lipemia--effect of lipid-lowering drugs.
    Karpe F
    Atheroscler Suppl; 2002 May; 3(1):41-6. PubMed ID: 12044585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia.
    Schonfeld G; Aguilar-Salina C; Elias N
    Am J Cardiol; 1998 Feb; 81(4A):43B-46B. PubMed ID: 9526813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetic dyslipidemia: a practical guide to therapy.
    Tovar JM; Bazaldua OV; Loffredo A
    J Fam Pract; 2008 Jun; 57(6):377-88. PubMed ID: 18544321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Place of fibrates for the treatment of patients with atherogenic dyslipidemia].
    Ducobu J; Scheen AJ; Legat P; De Backer G; Van Gaal L; Velkeniers B; Kartounian J; Maes M; Hermans M
    Rev Med Liege; 2009 Oct; 64(10):512-8. PubMed ID: 19911665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.